Blood vessel occlusion following vascular interventions is a major clinical problem and a multibillion commercial opportunity. Their product, APAC, uniquely targets both acute and late complications of vascular interventions and acts locally at the site of the vascular injury. These unique features enable them to focus – within the vast blood vessel occlusion market – first on selected fast track indications, i.e. life threatening conditions without approved therapies. They are driven to take these therapeutics through the clinic, enabling treatments for patients where currently no optimal options exist.
Aplagon partnered with Cadila Pharmaceuticals, an Indian multinational pharmaceutical company, in 2017 for the clinical development and commercialisation of its lead APAC product in India. Together the companies are pursuing selected challenging indications where the current treatments are not optimal. Aplagon is raising funding to prove the effectiveness and safety of APACs in human trials, after which the drug will be commercialised by 2021.
⊕ APAC does not directly compete with other current treatments and is solving problems that exist regardless of modern medicines optimal use.
⊕ The goal is to have a quick exit and increase in valuation – the companies target is to commercialise the product within 3 years.
⊕ APAC will be introduced to the market through acute kidney failure and dialysis patients – currently both patient groups have a large medical need but no effective treatments.
Interested in investing in this life changing health science company? Visit our Co-investment Platform, download the investor material and invest together with us (note: the investor material is only available in Finnish, please contact us for more information in english)
The funding round closes on 7.12.2018.
We are organizing an investor breakfast in November which will be streamed via live webinar 22.11.2018 at 8.30am, where Aplagons CEO Aki Prihti and CSO, Professor Riitta Lassila will introduce the company and go through the funding round in detail.